Clinical trial
E2022 Patch Formulation Single Dose Phase I Study
NCT01253434 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- E2022 Patch Formulation Single Dose Phase I Study
- Lead sponsor
- Eisai Co., Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2010
- Completion date
- March 31, 2011
- Enrollment
- 80 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
japanese healthy male adult volunteers